Disease burden of neonatal invasive Group B Streptococcus infection in the Netherlands

• Published in: PloS one 2019-05, Vol.14 (5), p.e0216749-e0216749
• Main Authors: de Gier, Brechje, van Kassel, Merel N, Sanders, Elisabeth A M, van de Beek, Diederik, Hahné, Susan J M, van der Ende, Arie, Bijlsma, Merijn W
• Format: Article
• Language: English
• Subjects: Antibiotic Prophylaxis; Antibiotics; Bacteremia - epidemiology; Bacterial meningitis; Biology and Life Sciences; Births; Blood; Blood culture; Blood tests; Care and treatment; Cerebrospinal fluid; Consultation; Culture; Diagnostic systems; Disease control; Disease Progression; Epidemiology; Estimates; Female; Health aspects; Health surveillance; Humans; Incidence; Infant; Infant, Newborn; Infection; Infections; Infectious diseases; Laboratories; Male; Medical research; Medicine and Health Sciences; Meningitis; Meningitis, Bacterial - epidemiology; Models, Biological; Mortality; Neonatal Sepsis - epidemiology; Neonates; Netherlands - epidemiology; Neurology; Neurosciences; Newborn babies; Newborn infants; Pregnancy; Pregnancy Complications, Infectious - drug therapy; Pregnancy Complications, Infectious - epidemiology; Prevention; Public health; Retirement benefits; Risk Factors; Sensitivity analysis; Sepsis; Streptococcal Infections - complications; Streptococcal Infections - epidemiology; Streptococcal Infections - prevention & control; Streptococcal Vaccines - pharmacology; Streptococcus; Streptococcus agalactiae; Streptococcus agalactiae - pathogenicity; Streptococcus infections; Systematic review; Trends; Vaccines; Womens health
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0216749

Group B Streptococcus (GBS) is the leading cause of neonatal sepsis and meningitis worldwide. We aimed to estimate the current burden of neonatal invasive GBS disease in the Netherlands, as a first step in providing an evidence base for policy makers on the potential benefits of a future maternal GBS vaccine. Surveillance of neonatal invasive GBS occurs at the National Reference Laboratory for Bacterial Meningitis, where culture isolates from cerebrospinal fluid and blood are sent by diagnostic laboratories. From the number of cultures we estimated the incidence of neonatal (age 0-90 days) GBS meningitis and sepsis. We constructed a disease progression model informed by literature and expert consultation to estimate the disease burden of neonatal invasive GBS infection. As many neonates with a probable GBS sepsis are never confirmed by blood culture, we further estimated the disease burden of unconfirmed cases of probable GBS sepsis in sensitivity analyses. An estimated 97 cases and 6.5 deaths occurred in the Netherlands in 2017 due to culture positive neonatal invasive GBS infection. This incidence comprised 15 cases of meningitis and 42 cases of sepsis per 100.000 births, with an estimated mortality of 3.8 per 100.000 live births. A disease burden of 780 disability-adjusted life years (DALY) (95% CI 650-910) or 460 DALY per 100.000 live births was attributed to neonatal invasive GBS infection. In the sensitivity analysis including probable neonatal GBS sepsis the disease burden increased to 71 cases and 550 DALY (95% CI 460-650) per 100.000 live births. In conclusion, neonatal invasive GBS infection currently causes a substantial disease burden in the Netherlands. However, important evidence gaps are yet to be filled. Furthermore, cases of GBS sepsis lacking a positive blood culture may contribute considerably to this burden potentially preventable by a future GBS vaccine.